Vivimed

Leveraging Global Presence

Partnering Innovation

Delivering Affordable Chemistry

Vivimed Labs Ltd

Investor Presentation – March 2019

Disclaimer

Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward looking statements.

Vivimed Labs Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

Table of Content

Vivimed

Vivimed at a Glance



Bulk generics	Niche generics	New generics	Ethical products
Anti-ulcer	Antihistamine, sedative, hypnotic	Anti-depressant	Antiparasitic agent (veterinary)
Antibiotic	Analgesic	Anti-convulsant	Anthelmintic
Antifungal	Anti-Hypertensive	Anti-parkinsonian	Antihistamine, Antipsychotic, Anxiolytic
Antiviral	Mydriatic	Anti-ulcerative	Skeletal muscle relaxants
	Vasodilator	Bone resorption inhibitor	
	Analgesic/Narcotic	Calcium channel blocker	

Filings



Vivimed Labs in Numbers

1991

Year of Foundation

2000+

# of Employees

12

No. of Facilities

6

R&D Facilities

APIs, FDFs, and Specialty Chemicals

Product Portfolio

Across 3 Continents (Europe, Asia, North America) covering 5 countries

Market Presence

₹11,857 Mn

Revenues (FY18)

₹2,216 Mn

EBITDA (FY18)

₹761 Mn

PAT (FY18)

Business Snapshot

Key Developments - Milestones

UQUIFA

- $ 55 Mn acquisition
- Added depth to the API portfolio
- Enabled servicing European & American market effectively

Actavis Pharma

- Rs. 122 cr acquisition
- Provided access to regulated market – FDF business
- USFDA approved facility with a capacity to produce 1.2 bn Solid Oral Dosages p.a.

Divested Personal care Division

- Divested part of Specialty Chemicals business for an EV of Rs. 380 cr
- Divestment follows Company's strategy of focusing on core Pharmaceuticals business

Investment by Orbimed

- $ 50 Mn Investment in Mascerene, overseas subsidiary
- Fund Deployment - Debt reduction & Development of API business
- Investment testament to Company's proven track record

Soneas Acquistion

- € 15 Mn acquisition
- Transformed UQUIFA into an end-to-end solution provider
- Offered access to new / untapped geographies

JV with Strides

- 50:50 JV with Strides to develop and commercialize various ANDAs in US
- Vertical Integration of APIs & exploitation of mutual formulation capabilities
- Looking to achieve 5 ANDAs per year from this JV in the complex generics space

Our Distinguished Clientele

Vivimed

Management Team

DR. V MANOHAR RAO

Chairman

- Conceptualized and started 'VVS Pharmaceuticals and Chemicals Private Limited ("VVS")', (which now stands merged with Vivimed Labs Limited).
- Retired as Joint Director of The Veterinary Biological and Research Institute (VBRI).
- Post- graduation in Veterinary Sciences from Edinburgh University, U.K. and has more than 30 years experience in The Municipal Corporation of Hyderabad and Department of Animal Husbandry, Government of Andhra Pradesh (India).

SANTOSH VARALWAR

Managing Director & CEO

- First generation entrepreneur
- Business growth strategy and leadership; Focus on key global Client relationships
- Previously associated with Shipping Corporation of India

SANDEEP VARALWAR

Executive Director & SBU – Head FDF

- Associated with Vivimed since its incorporation and leads Vivimed's Healthcare FDF division
- Over 19 years of experience in manufacturing and marketing in the Healthcare industry

MARK I ROBBINS

CEO - UQUIFA

- Mr. Robbins has been the CEO of UQUIFA since 1990
- Has had experience managing other chemical and pharmaceutical companies for 20 years
- Holds a BSc (Hons) in Genetics and an MBA

SAURABH SG

Executive Director - UQUIFA

- 9+ years of past experience in Investment Management
- B.E. degree in Mechanical Engineering, MBA in Finance & International Business; pursued courses in 'emerging business leadership' at the IIM, Bangalore, London Business School and INSEAD, Paris

RAMAKRISHNA CHUNDURI

Member of Advisory Board

- Qualified Chartered Accountant and Cost Accountant
- Finance professional with varied experience in finance and management over a few decades.
- Associated with several companies including DEL, Matrix Labs, Maa TV etc and served as a director in many companies.

JOZSEF REPASI

Managing Director - Soneas

- More than 25 years of experience in pharmaceutical research and development.
- Associated with Soneas from 1996.
- Msc. In Pharmaceutical Development from Eötvös Loránd University.
- Head of Research and Development at Prochem Ltd, UNIDO Headquarters Vienna.

SANKETH VARALWAR

SBU – Head (Specialty Chemicals) Director – Vivimed Labs Europe Ltd.

- Seasoned Professional ,Over 2 decades of experience in Sales and Marketing in US/Europe.
- B.E. degree in Computer Engineering.
- Assumed responsibility as SBU head in FY 15 and registered a phenomenal growth for the Spechem business.

Business Divisions…



Vivimed

Business Divisions

- ✓ Global supplier of niche molecules and formulations (Pharmaceuticals)
- ✓ Integrated player – presence across critical components in value chain
- ✓ US FDA approved world class manufacturing facilities

Active Pharmaceutical Ingredient & CDMO

- ➢ UQUIFA s.a., Spanish subsidiary with 80 years of experience with USFDA approved manufacturing units in Spain(2) and Mexico(1) manufactures API for Pharmaceuticals and animal health industry globally
- ➢ Accounts for 50% of the overall revenue

Finished Dosage Formulation

- ➢ Value added business delivering quality formulations and offering novel drug systems
- ➢ Present in generic, branded and contract manufacturing segments
- ➢ Accounts for 38% of the overall revenue

Specialty Chemicals (under divestment)

- ➢ Manufactures Hair Dyes, Photochromic Dyes, Anti-Microbials and Imaging Chemicals
- ➢ Vivimed is a world leader in the development of innovative photochromic dyes
- ➢ Vivimed has patented processes for novel dyes targeting a range of applications

Product wise Sales Mix (%)



Geography Mix (%)



Vivimed

Sector Overview

Pharmaceuticals

Vivimed

Pharmaceutical Industry – Overview (Global)

$ 1.4 Tn

Global spending on medicines by 2022 (expected)

$ 3.9 bn

Spending on branded medicine in developed market (past 5 years) as per IQVIA Institute

37%

Increase in patent expiry between 2018-2022

$1415 - $1445 bn

Global medicine spending by 2022 (Forecasted)

Source: Industry Reports

Global Spending by Region (2007)



Global Spending by Region (2017)



Global Spending by Region (2022)



Source: Industry Reports

Developed markets Pharmerging markets Rest of the World

Pharmaceutical Industry – Developed Markets

$ 915-945 bn Pharmaceutical spending in developed markets by 2022

United States



- US pharmaceutical market is estimated to grow by 4-7% CAGR from US$ 466.6 Billion in 2017 to US$ 585-615 Billion in 2022
- Price increases and introduction of new specialty medicines to drive the growth

Europe



- CAGR for the next five years for EU5 markets is estimated at 1-4%, with overall spending in these markets likely to escalate from US$ 154.4 Billion in 2017 to US$ 170-200 Billion in 2022
- Ageing population of countries and increased incidence of chronic ailments to drive the growth

Source: Industry Reports

Pharmaceutical Industry – Pharmerging Markets

$ 345-375 bn Pharmaceutical spending in Pharmerging markets by 2022

Region / country	2017	2013-17 CAGR	2022	2018-22 CAGR
China	122.6	9.4%	145-175	5-8%
Tier 2 Markets	67.3	11.2%	89-93	7-10%
Brazil	33.1	11.5%	38-42	5-8%
India	19.3	11.0%	26-30	9-12%
Russia	14.9	10.8%	20-24	7-10%
Tier 3 markets	79.7	8.9%	95-125	6-9%
Total	**269.6**	**9.7%**	**345-375**	**6-9%**

- Branded generic medicines comprise the largest proportion of medicine spending in these economies
- China, the largest pharmerging market, will grow at a modest 5-8% in the next half decade, reaching US$ 145-175 Billion in 2022
- India and Russia are expected to grow faster, in comparison, averaging at 10% in the same time span, while the other pharmerging markets will average 6-9%
- India's spending on medicines will propel its entry into the top 10 countries in 2018, and to the ninth position overall between 2019 and 2022



Source: Industry Reports



Notes: Spending per capita, per capita growth and overall spending growth in Constant US$.

API & CDMO Business (UQUIFA & SONEAS)

Vivimed

Global presence: a strategic advantage

A global platform that combines quality with competitiveness

Leveraging Global Presence

Global Platform provides Strategic advantage

- UQUIFA operates across Spain, Mexico, Hungary, and India with a strong transnational management team.
- Global customer base with clients in more than 70 countries worldwide.
- Pharma Co has 42 distributor arrangements across 56 countries.

Trusted Franchise in its markets

- Combination of quality manufacturing and track record of reliability with marquee clients.
- Switching sources of API supply is not easy due to evolving industry dynamics and importance of compliance position
  - These have become barriers of entry and are now benefiting experienced players like UQUIFA.
- A strong “under-development” pipeline of new products.
- In terms of intellectual property, more than 150 active DMFs filed and 20 CoS approved.
- More than 75 years of experience in the pharmaceutical industry.

UQUIFA Group in Numbers

Acquired in 2011, UQUIFA is home to our API business comprising of generics & Contract development and manufacturing organisation (CDMO)

Rich Heritage – Serving leading pharmaceutical and animal health companies in Spain and Mexico for the last 8 decades

Strategically located Manufacturing Unit – Spain (2), Mexico (1)

Global Presence – Spanish facilities to meet / cater European Market; Mexican facility to supply to US market

75%
API %
(Revenue share)

25%
CDMO %
(Revenue share)

70%
Spain
(Geography mix)

30%
Mexico
(Geography mix)

4
Multi-Product plants across continents

40+
Type II Drug Master Files (DMFs) filed with USFDA

150
Active DMFs filed Worldwide

Vivimed

Timelines and key milestones

Consistent record of reliability and adherence to quality standards

UQUIFA Incorporation

- UQUIFA was founded as a manufacturers of opiates and FDF to pharmacies.
- UQUIFA became a leading supplier to Spanish pharmacies.

Takeover by HCH

- Acquired by Holliday Chemical Holdings, a UK based chemical company.
- UQUIFA acquired Barisintex with its headquarters and facilities in Sant Celoni, widening production capability

Acquisition of the Mexican site

- UQUIFA acquired a new chemical plant in Mexico from SKB. This acquisition established the 3 manufacturing locations which UQUIFA operates today.
- In 1998, Holliday Chemical Holdings was acquired by Yule Catto Plc.

Acquired by Vivimed

- Acquired by Vivimed Labs, a India based healthcare and specialty chemicals company.
- Investments stepped up on manufacturing plants, product mix, and people.

Focus on growth

- UQUIFA is now focused on pursuing growth through a mix of CDMO and Generic API.
- Stronger client mining, new product filings, compliance and operational excellence being focus areas.

Soneas acquisition

- Raised capital from OrbiMed Asia, a healthcare focused PE firm.
- Soneas acquisition completed which brings phase 1–2 capability, new customer base, chemistry capabilities and greater coverage of the CDMO sector.

Vivimed

What is UQUIFA's core positioning ?

Originator and Generic customers require support for chemical intermediates and API production in both the development and commercial phases

Drug development

UQUIFA's core positioning

Research phase	Development phases I, II and III	High-scale manufacturing for commercial phase	Marketing	Distribution and sales
Research requires highly skilled experts that supply research pipelines with novel and innovative molecules.	Development includes both synthetic, analytical, and regulatory/administrative services.	Production process requires both production capacity and industrial expertise.	Marketing has become increasingly important over the last several years as a means of differentiation and maximizing the revenue potential of a given therapeutic.	Distribution requires logistics and coverage networks. A robust sales force is also required to negotiate volume, discounts and promote products.

Drug manufacturing

UQUIFA's core positioning

Building blocks	Intermediates	API	Formulation and production	Packaging
Building blocks are the basic chemical ingredients involved in chemical / API synthesis.	Substances resulting from the conversion of reactants into a product and that are used for the proceeding steps in a chemical reaction.	Technical expertise in the development and manufacturing of a wide range of APIs	APIs are mixed with excipients based on a specific formulation for drug delivery.	Drug packaging and distribution.

UQUIFA Group's – Manufacturing Facilities

	Lliçà de Vall Spain	St Celoni Spain	Cuernavaca Mexico	Budapest Hungary
Capacity	140, 000 L	170, 000 L	180, 000 L	208, 000 L
Number of reactors	29 reactors	29 reactors	30 reactors	58 reactors
Last US FDA Inspection	September 2015 Yes	May 2017	July 2018 Yes	—
8c-GMP Approval	June 2011 Yes Multipurpose	Yes	June 2011 Yes Multipurpose	Yes
Korean FDA Japanese Certification	Mercaptan incinerator, biological effluent treatment	June 2011 Yes Multipurpose	Biological effluent treatment off-site	—
Pilot plant in site	Sulphur chemistry, wiped film evaporation, hydrogenation, micronisation, sieving	Biological effluent treatment	Nitration, hydrogenation, in-situ prep, chlorination	—
Residues treatment on-site				Multipurpose
				Catalytic incinerator, off-site waste treatment
Technical expertise		Sulphur chemistry, roller compact unit, micronisation, sieving, lyophilisation		Optical resolutions, cryogenic and organometallic, high temperature, cyclopropanation, phosgenation (triphosgene), hydrogenations, halogenations, acid chloride preparations, carbene additions, diazotizations, Friedel-Crafts reactions, isomerizations, cyanations, carbonylation with CO

Regulatory expertise

Highly trained regulatory experts at each site with experience in all major geographies

- Filing Experience in all major geographies
  - Over 50 Type II DMF's filed with the FDA
  - More than 150 active DMF's worldwide
- Over 25 valid Certificates of Suitability
- Many years of successful regulatory audits by different agencies

Registration Dossier: Capabilities

- UQUIFA developed registration dossiers with in-house APIs and is well versed with EU filings and ANDAs for the USA
- UQUIFA works with partners to develop the formulation, perform the bio-equivalency and files the dossier to obtain Marketing Authorizations
- UQUIFA is willing to license either the dossier and/or the Marketing Authorization

Dossiers - Spain

Omeprazole 20mg, 40mg caps Pantoprazole 20mg, 40mg FCT Duloxetine 30mg, 60mg caps Linezolid 600mg FCT

Linezolid 2mg/ml 300ml bags Erlotinib 100mg, 150mg tablets

Generics – Firepower in existing products

Products	Regulated Market volume (MT)	Growth rate in target markets (%)	UQUIFA's Volume share (%)	Strategy
Omeprazole	310	5-6	**20**	• Establish cost advantage • Increase capacity
Quetiapine	215	6-9	5	• Increase new filings • Enhance sales outreach
Pantoprazol	260	10-12	**10**	• Establish cost advantage • Enhance sales outreach
Ranitidine	660	1-2	**25**	• Leverage on favourable market dynamics • Drive sales by undertaking debottlenecking
Doxylamine Succinate	21	5-6	**35**	• Develop niche product • Strengthen positioning
Ciprofloxacine	680	1-3	6	• Leverage on favourable market dynamics • Drive sales by undertaking debottlenecking
Terbinafine	75	4-5	2	• Improve cost position significantly • Drive sales in growing markets
Etofenamate	30	3-5	**60**	• Develop niche product • Drive sales by undertaking • debottlenecking

Vivimed

New generic pipeline

Under development

Products	Therapeutic Category	Trademark
Apixaban	Anti thrombotic	Eliquis
Bilastine	Antihistamine	Bilaxten
Brexpiprazole	Anti psychotic	Bilaxten
Brivaracetam	Anti epileptic	Briviact
Dabigatran	Anti thrombotic	Pradaxa
Edoxaban	Anti coagulant	Savaysa USA, Lixiana in EU
Lesinurad	Antigout	Zurampic
Mebendazole	Anthelmintic	Vermox
Minocycline	Antibiotic	Minocin
Mirabegron	Overactive bladder	Myrbetriq
Pimavanaserin	Parkinsons treatment	Nuplazid
Ricobendazole	Anthelmintic	Albendazole sulfoxide
Tapentadol	Analgesic	Nucynta
Tavoborole	Anti fungal	Kerydin
Apixaban	Anti thrombotic	Eliquis

Vivimed

CDMO

Vivimed

Why UQUIFA for CDMO?

Vivimed

Protection

We protect your intellectual property

Quality

Strong quality system approved by regulators and customers

Expertise

Technical expertise in the development and manufacture of wide range of API’s

Integration

Backward integration ensures cost efficient operations and the location of our manufacturing base a source of risk mitigation.

Flexibility

Flexible and adaptable to fulfil your needs

GILEAD HORIZON PHARMA ferrer GALDERMA Lundbeck abbvie Pfizer gsk

CDMO platform

Evolving constantly

Based in Barcelona, Spain, we are one of the first API/ advanced intermediates manufacturing companies offering R&D and cGMP manufacturing across three continents. Post Soneas acquisition, we also use manufacturing facilities in Budapest, Hungary.

Services include:

- Development of novel synthetic routes and optimisation of existing laboratory processes
- Scale-up from Laboratory to Pilot Plant
- Scale-up from Pilot Plant to commercial
- Optimising laboratory developed routes of synthesis to reduce isolation steps, improve yield, reduce batch production time and eliminate the use of toxic and/or dangerous reagents
- Transfer of commercial scale processes

Vivimed

Chemistry capabilities

- Grignard reactions & Organometallic Chemistry
- Fisher esterification & trans-esterification
- Chiral Synthesis, Chiral resolution and Asymmetric Synthesis
- Borane derivatives & coupling reactions
- Heck reactions
- Ozonolysis
- Halogenations, Nitrations and Sulphur Chemistry
- Hydrogenations (up to 5 bar) & reductions with reductive agents and different kind of hydrides
- Triphosgene reactions (industrial precursor for phosgene)
- Protection & de-protection Chemistry
- Solid phase reactions
- Crystallisation
- PSD expertise
- Polymorphism Studies
- Pellets manufacturing capability in Spain

Vivimed

Development and scale up capability

International R&D

Spain and Mexico R&D Lab

Custom synthesis, process improvement

- Capable of producing compounds from 1g to 1kg
- Small-scale glassware up to 20L glass reactors
- Make processes scalable, safe and environmentally friendly:
  - Reduces isolation steps
  - Improves yield
  - Minimizes batch production time
  - Eliminates use of toxic and/or dangerous reagents

Dedicated Analytical group for method development

- HPLC, GC-MS, IR, UV, TGA, DSC, PSD (Malvern Mastersizer and Air-Jet)

Spain and Mexico Pilot Plant

Scale-up and small scale production

- Producing 1kg to multi-kg quantities for Phase I, II and III clinical trials and for small scale commercial production
- Variety of vessel sizes and materials of construction

Installations are flexible allowing many combinations of reactors, filters and dryers

- Cryogenic capability
- Ozonolysis, hydrogenation and nitration

Qualified technicians run the plants under cGMP, on FDA approved sites

- The quality control systems in the PP are identical to those used for commercial production

CDMO case study

- R&D product from US Biotech company
- Therapeutic area: ARV compound, VIH
- 5 different FDF
- 5 reaction steps
- Industrial challenge: nucleoside chemistry, hybride reaction



Soneas' Offerings



Soneas Research

➢ **Product Development –**

- Rapid development of APIs and their intermediaries
- Custom contract manufacturing of cGMP APIs and their intermediaries (laboratory to pilot plant scales)

7
Laboratories

20
Chemists & Support

4.4m3
Reactor Capacity



Soneas Chemicals

➢ **Large Scale non-cGMP contract manufacturing –**

- Rapid development of APIs and their intermediaries

200m3
Reactor Capacity

Soneas has advanced capabilities in new chemical entity (NCE) development as well as emerging technologies such as metal catalysis and heterocyclic chemistry. It also has capabilities for varied end usage, which includes neurology, dermatology, metathesis catalysts and synthetic hormones.

Soneas Facilities

Soneas Research

R&D laboratories:

- 7 research labs
- 3 analytical labs
- NMR lab

Pilot Plant (7847 m2):

- 1 kilo lab
- 1 analytical lab
- 1 IPC lab
- 2 process & scale-up labs
- 3 pilot plant production units

Soneas Chemicals

Large scale manufacturing site (63.000 m2):

- 2 production units
- Hydrogenation unit
- Distillation unit
- Drying and packaging unit



Reactor capacity – 208,000 L

Vivimed

CDMO – Value Proposition

- Integrated solution provider following acquisition of Soneas
- Protect clients' intellectual property
- Strong quality-control system approved by regulators and customers
- Technical expertise in manufacturing a wide range of APIs benefits in the co-development of the CDMO products
- Higher cost-efficiencies owing to backward integration in the business

Key Strategic Focus Areas

Achieve stronger client mining

Expand therapeutic portfolio across anti-ulcers, Central Nervous System (CNS) and Cardio Vascular System (CVS) categories

Determine correct pricing to strengthen competitive positioning

Continue to grow the high-potential CDMO business

Launch new products in generics business with focus on customer-driven projects

Innovating on co-development options to build stable, profitable growth

UQUIFA dynamics

A summary of growth drivers in generics and CDMO

Vivimed

Generics

- Molecule portfolio with growing demand in areas such as anti- ulcer, CNS, and CVS
- Operational and cost efficiency is improving market share Expansion in Japan, Korea, and India
- Competitive advantage of regulatory compliance
- Pipeline of new products and improving market shares in Generic 50+ DMFs and 20+ approved CoS

CDMO

- Industry with a 6–7% annual growth
- Operational and cost efficiency is expanding market share
- Growth in EU, USA ,and Japan with Soneas technology
- Competitive regulatory advantage and compliance Increased
- capacity — Phase 1/2, NCE (Soneas)
- Full range "Lab — Pilot — Commercial Production"

Future growth drivers

Looking forward



Generic API

- Growth from current products; more products per customer, more customers per product.
- New products to secure future growth.

Soneas Platform

- Opportunity to leverage UQUIFA large scale platform.
- Access to new technologies and big pharma customer base in EU and Japan geographies.
- Higher volume off-take for UQUIFA assured and better value retention for the Group.

CMO API

- Leveraging strengths of chemistry and manufacturing presence in the EU/NA.
- Scale up of current relationship likely and leveraging of preferred supplier relationships with big pharma.

Vivimed

FDF

Vivimed

Finished Dosage Formulation

- Value added business with focus on delivering quality and novel drug formulation
- Present in generic, branded and contract manufacturing segments
- Capacity – 2 bn solid oral dosages
- Strategic tie-up with Strides Shasun to expand business in US
- Marquee clients – GSK, Dr. Reddy's, Cipla, Merck Serono etc.
- Focused on expanding into non – USA based regulated generic markets such as CIS and African countries



Vivimed

Facilities Overview

Jeedimetla Hyderabad

PICs/NDA/WHO-GMP approvals

Kashipur, Uttarakhand

ISO 9001-2000; ISO 4001 & OHSAS 18001 certifications

WHO-GMP/ NAFDAC approvals

Klar-sehen, Hyderabad

ISO 13485 certified

CE certificate for medical devices

Haridwar Uttarakhand

2000, ISO 14001 and OHSAS 18001 certifications

ISO 13485 certified

Bolarum Hyderabad

Alathur, Tamil Nadu,

(Now part of JV with Strides)

USFDA Approved Facility

Key Strengths



Vivimed

Partnering Innovation

Vivimed

Partnership with Innovator Companies



Vivimed

JV with Strides : Win - Win proposition

Vivimed

Molecules commercialized under JV

Particulars	Amlodipine Besylate	Donepezil Hydrochloride	Losartan Potassium	Metronidazole	Zolpidem Tartrate
Brand name	Norvasc	Aricept	Cozaar/Hyzaar	Flagyl	Ambien
Innovator	Pfizer	Eisai	Merck & Co.	Pfizer	Sanofi
Global sales ($ Mn)	312	200	500	44	50
# ANDA filers	373	91	113	99	79
First launched/ approved	1987	1996	1995	1963	1992
Uses	• Hypertension • High blood Pressure • Coronary artery Disease	• Dementia of Alzheimer's Disease	• Hypertension • Lower blood pressure in adults	• Bacterial vaginosis in non-pregnant Women	• Insomnia characterized by Difficulties with sleep initiation

Recent Approvals:

- Ranitidine
- Azithromycin
- Nadolol
- Enalapril Maleate

ANDAs Awaiting Approval:

- Albendazole: CRL Responded
- Solifenacin Succinate: ANDA submitted
- Ibesartran: CBE filed (Awaiting launch)
- Acyclovir: CBE filed (Awaiting launch)

Delivering Affordable Chemistry

Vivimed

Delivering Affordable Chemistry

IP Protection

- We ensure all IPs are safe at all stages.

Right Chemistry

- Good R&D teams with highly accomplished professionals across all locations – Spain, Mexico, Hungary and India.
- State-of-the- art R&D equipment.
- Experience of working on development phases I, II and III, and scale up from lab to commercial scale.

Cost Effective

- Manufacturing plants spread across Spain, Mexico and Hungary are all well recognized cost effective manufacturing hubs with demonstrated manufacturing capabilities.

Regulatory Compliances

- FDA approved plants in Spain (2) and Mexico (1).
- cGMP approved R&D facilities in Soneas.
- 150+ active DMFs filed worldwide and 40+ type II DMFs filed with US FDA.

Expertise

- Technical expertise in the development and manufacture of wide range of API's.

Integration

- Backward integration ensures cost efficient operations and the location of our manufacturing bases a source of risk mitigation.

Flexibility

- Flexible and adaptable to fulfil all the customer needs.

Vivimed

Growth Levers

- Launching formulations based on UQUIFA APIs in India and other parts of the world
- Developing innovative formulations across multiple delivery formats for different parts of the world
- Bolstering revenues and strengthening position in the formulations business through JV with Strides Shasun
- Strengthening filing pipeline of four to six new files every year
- Ramping up the Contract Research and Manufacturing Services (CRAMS) business
- Achieving optimum utilization of existing capacities



Specialty Chemicals Business

Vivimed

Overview

Description

- Manufacturing active ingredients for home care, personal care and industrial products
- Product range - hair dyes, photochromic dyes, photochromic products, anti-microbials and imaging chemicals
- Maintains leadership position through captive manufacturing (Bidar-Karnataka) or with other partnerships
- Current portfolio consists of 100+ products serving 300 + Customers with supply expertise for any volumes
- Vivimed maintains world-class R&D capabilities with scientists who have a combined dye chemistry experience of greater than 100 years, both in Huddersfield-UK and Hyderabad-India.

Recognitions

- R&D certified as a GLP Laboratory by CISR - a government of India undertaking
- Awards from Johnson & Johnson– Quality Promise to Zero Defect in 2010 and Implementation of Supplier Enabled Innovative Idea in 2005
- Certificate of Appreciation from Hindustan Unilever Limited in 2009
- Recipient of the Queens Award in 2008
- UK's R&D team got the Centenary Medal by The Society of Dyers and Colorists (SDC) for Photochromic Dyes in 2005

Manufacturing Facilities

Manufacturing Facility – Bidar, India (Since 1991)

- Designed in compliance with US FDA norms & highest environmental standards
- Environmental certification: ISO 9001: 2008 QMS and ISO 14001:2004; Safety Management system ISO 18001: 2007

Research & Development Facilities- Nacharam in India and Huddersfield in UK

- Focus on idea-generating research right from creation of molecule and collaborative manufacturing

Top Customers

Hair Dyes

COSMOTEC

COTY

L'ORÉAL

Henkel

OMNICHEM

MASSÓ

UNION

PARCHIMY

EUGENEPERMA PARIS

WOOSUNG Cosmetic & Trading

Photochromatic

CORNING

Henkel

MILDEX MILDEX OPTICAL INC.

Keystone Innovation in Color Solutions

VISION EASE®

Mitsui Chemicals Group

WEIXING OPTICS

Financial Overview

Vivimed

Financial Highlights – 9M & Q3 FY19

Vivimed

9M FY19

Revenues (Rs. cr)



EBITDA (Rs. cr)



PAT (Rs. cr)



Q3 FY19







Segmental Performance – 9M & Q3 FY19

Pharma Business



- Revenues grew by 12% y-o-y to reach Rs. 839 cr.
  - Profitability though remained muted, with EBIT of Rs. 83 cr for 9M FY19
  - Margins for 9M stood at 9.9% as against 12.4% for 9M FY18

Specialty Chemicals Business



- Revenue from the business stood at Rs. 129 cr for 9MFY2019 stood lower by ~15% compared to the same period last year.
  - Profitability as well declined by 20% with EBIT of Rs. 39 cr for 9M FY19

Debt Movement



* September 2018 debt figure shown as Rs. 882 cr in last quarter's Investor presentation was represented incorrectly and was actually Rs. 901 cr

Vivimed has been focussed towards debt reduction and reducing the cost of funds.

Figures in Rs. Crore, as per IndAS

Consolidated P&L Statement

Rs Crs.

Particulars	Q3 FY19	Q3 FY18	Y-o-Y	9M FY19	9M FY18	Y-o-Y
Revenue	243.9	299.6	***-18.59%***	967.1	900.1	***7.44%***
Cost of Material Consumed	89.3	128.2	***-30.34%***	381.59	371.02	***2.85%***
Employee Expenses	42.3	52.3	***-19.12%***	166.1	139.5	***19.07%***
Other Expenses	75.6	70.2	***7.69%***	263.7	211.6	***24.62%***
EBITDA	36.7	48.9	***-24.95%***	155.71	177.98	***-12.51%***
EBITDA Margin	15%	16%	***(100 bps)***	16%	20%	***(400 bps)***
Other Income	6.3	3.1	***103.23%***	17.1	6.7	***155.22%***
Depreciation	15.3	13.9	***10.07%***	50.7	42.6	***19.01%***
EBIT	27.8	38.1	***-27.03%***	122.1	142.1	***-14.07%***
EBIT Margin	11%	13%	***200 bps***	13%	16%	***(300 bps)***
Interest / Finance Cost	17.6	17.2	***2.33%***	54.4	63.1	***-13.79%***
PBT	10.2	20.9	***-51.20%***	67.7	79	***-14.30%***
Tax Expense	-0.6	-0.02	*** - ***	10.1	12.1	***-16.53%***
PAT	10.8	20.9	***-48.33%***	57.6	66.9	***-13.90%***
% Margin	4%	7%	***-36.52%***	6%	7%	***-19.87%***

figures as per Ind AS

Profitability over Years

Net Revenue (Rs. cr)



EBITDA (Rs. cr) & Margin (%)



PAT (Rs. cr) & Margin (%)



*Financial results are not strictly comparable with the results of FY 2017 as revenues from sale of divested business to Exeltis and Clariant India are included in FY 17.

Represents the normalised numbers for one- time gain from sale to Exeltis and Clariant India Ltd.

Thank You

Sunil Arab

Sunil.Arab@vivimedlabs.com

Gavin Desa / Suraj Digawalekar

+022 6645 1237 / 19

gavin@cdr-india.com

suraj@cdr-india.com

Vivimed